The molecular characterization and therapeutic strategies of papillary renal cell carcinoma

References

• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67:507–524.
   PubMed Web of Science ®Google Scholar
• Borgmann H, Musquera M, Haferkamp A, et al. Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients. World J Urol. 2017;35:1891–1897.
   PubMed Web of Science ®Google Scholar
• Bellut J, Bertz S, Nolte E, et al. Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma. Sci Rep. 2017;7:16424.
   PubMed Web of Science ®Google Scholar
• Wach S, Nolte E, Theil A, et al. MicroRNA profiles classify papillary renal cell carcinoma subtypes. Br J Cancer. 2013;109:714–722.
   PubMed Web of Science ®Google Scholar
• Koscianska E, Baev V, Skreka K, et al. Prediction and preliminary validation of oncogene regulation by miRNAs. BMC Mol Biol. 2007;8:79.
   PubMed Web of Science ®Google Scholar
• Nadiminty N, Tummala R, Lou W, et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012;287:1527–1537.
   PubMed Web of Science ®Google Scholar
• Ricketts CJ, De Cubas AA, Fan H, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:313–26.e5.
   PubMed Web of Science ®Google Scholar
• Giles RH, Choueiri TK, Heng DY, et al. Recommendations for the management of rare kidney cancers. Eur Urol. 2017;72:974–983.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905.
   PubMed Web of Science ®Google Scholar
• Ren Q, Wang L, Al-Ahmadie HA, et al. Distinct genomic copy number alterations distinguish mucinous tubular and spindle cell carcinoma of the kidney from papillary renal cell carcinoma with overlapping histologic features. Am J Surg Pathol. 2018;42:767–777.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005;65:5628–5637.
   PubMed Web of Science ®Google Scholar
• Brunelli M, Eble JN, Zhang S, et al. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol. 2003;16:1053–1059.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Tardanico R, Balzarini P, et al. Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet Cytogenet. 2010;199:128–133.
   PubMedGoogle Scholar
• Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177–183.
   PubMed Web of Science ®Google Scholar
• Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–145.
   PubMed Web of Science ®Google Scholar
• Pal SK, Ali SM, Yakirevich E, et al. Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling. Eur Urol. 2018;73:71–78.
   PubMed Web of Science ®Google Scholar
• Skala SL, Xiao H, Udager AM, et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol. 2018;31:179–197.
   PubMed Web of Science ®Google Scholar
• Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73.
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12:3657–3660.
   PubMed Web of Science ®Google Scholar
• Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98:3387–3392.
   PubMed Web of Science ®Google Scholar
• Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151:561–566.
   PubMed Web of Science ®Google Scholar
• Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95–106.
   PubMed Web of Science ®Google Scholar
• Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol. 2009;29:4080–4090.
   PubMed Web of Science ®Google Scholar
• Shuch B, Linehan WM, Srinivasan R. Aerobic glycolysis: a novel target in kidney cancer. Expert Rev Anticancer Ther. 2013;13:711–719.
   PubMed Web of Science ®Google Scholar
• Sandhu IS, Maksim NJ, Amouzougan EA, et al. Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1). Biochem Soc Trans. 2015;43:650–656.
   PubMed Web of Science ®Google Scholar
• Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011;20:511–523.
   PubMed Web of Science ®Google Scholar
• Li S, Shuch BM, Gerstein MB. Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations. PLoS Genet. 2017;13:e1006685.
   PubMed Web of Science ®Google Scholar
• Kovac M, Navas C, Horswell S, et al. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat Commun. 2015;6:6336.
   PubMed Web of Science ®Google Scholar
• Hong Q, Li O, Zheng W, et al. LncRNA HOTAIR regulates HIF-1alpha/AXL signaling through inhibition of miR-217 in renal cell carcinoma. Cell Death Dis. 2017;8:e2772.
   PubMed Web of Science ®Google Scholar
• Tan SK, Pastori C, Penas C, et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Mol Cancer. 2018;17:74.
   PubMed Web of Science ®Google Scholar
• Ali MM, Akhade VS, Kosalai ST, et al. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nat Commun. 2018;9:883.
   PubMed Web of Science ®Google Scholar
• Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2018;28:287–301.
   PubMed Web of Science ®Google Scholar
• Huang C, Yuan N, Wu L, et al. An integrated analysis for long noncoding RNAs and microRNAs with the mediated competing endogenous RNA network in papillary renal cell carcinoma. Onco Targets Ther. 2017;10:4037–4050.
   PubMed Web of Science ®Google Scholar
• Saleeb RM, Plant P, Tawedrous E, Krizova A, Brimo F, Evans AJ, et al. Integrated phenotypic/genotypic analysis of papillary renal cell carcinoma subtypes: identification of prognostic markers, cancer-related pathways, and implications for therapy. Eur Urol Focus. 2016;16:S2405–4569.
   PubMedGoogle Scholar
• Wala SJ, Karamchandani JR, Saleeb R, et al. An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways. Mol Oncol. 2015;9:1667–1677.
   PubMed Web of Science ®Google Scholar
• Ooi A, Dykema K, Ansari A, et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res. 2013;73:2044–2051.
   PubMed Web of Science ®Google Scholar
• Hohmann AF, Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet. 2014;30:356–363.
   PubMed Web of Science ®Google Scholar
• Heller G, Altenberger C, Steiner I, et al. DNA methylation of miRNA-encoding genes in non-small cell lung cancer patients. J Pathol. 2018;245:387–398.
   PubMed Web of Science ®Google Scholar
• Wang S, Huang Y, Mu X, Qi T, Qiao S, Lu Z, et al. DNA methylation is related to the occurrence of breast cancer and is not affected by culture conditions. Mol Med Rep. 2018;17:7365–7371.
   Web of Science ®Google Scholar
• Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–474.
   PubMed Web of Science ®Google Scholar
• Hughes LA, Melotte V, de Schrijver J, et al. The CpG island methylator phenotype: what’s in a name? Cancer Res. 2013;73:5858–5868.
   PubMed Web of Science ®Google Scholar
• Yanokura M, Banno K, Adachi M, et al. Genome-wide DNA methylation sequencing reveals miR-663a is a novel epimutation candidate in CIMP-high endometrial cancer. Int J Oncol. 2017;50:1934–1946.
   PubMed Web of Science ®Google Scholar
• Modi PK, Singer EA. Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis. Ann Transl Med. 2016;4:143.
   PubMed Web of Science ®Google Scholar
• Ge YZ, Xu LW, Xu Z, et al. Expression profiles and clinical significance of MicroRNAs in papillary renal cell carcinoma: a STROBE-compliant observational study. Medicine (Baltimore). 2015;94:e767.
   PubMed Web of Science ®Google Scholar
• Breunig C, Erdem N, Bott A, et al. TGFbeta1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer. Mol Oncol. 2018;12:1447–1463.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35:2687–2697.
   PubMed Web of Science ®Google Scholar
• Schuller AG, Barry ER, Jones RD, et al. The MET inhibitor AZD6094 (savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models. Clin Cancer Res. 2015;21:2811–2819.
   PubMed Web of Science ®Google Scholar
• Schoffski P, Wozniak A, Escudier B, et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer. 2017;87:147–163.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French genitourinary group (GETUG)dagger. Ann Oncol. 2015;26:1123–1128.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35:2993–3001.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31:181–186.
   PubMed Web of Science ®Google Scholar
• Gardie B, Remenieras A, Kattygnarath D, et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet. 2011;48:226–234.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–366.
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Zhang J, Shi F, et al. Expression of PD-1 on CD4(+) tumor-infiltrating lymphocytes in tumor microenvironment associated with pathological characteristics of breast cancer. J Immunol Res. 2018;2018:5690258.
   PubMedGoogle Scholar
• Johnson DB, Bordeaux JM, Kim JY, et al. Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin Cancer Res. 2018.
   Web of Science ®Google Scholar
• Chen L, Diao L, Yang Y, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 2018;8:1156–1175.
   Web of Science ®Google Scholar
• Motoshima T, Komohara Y, Ma C, et al. PD-L1 expression in papillary renal cell carcinoma. BMC Urol. 2017;17:8.
   PubMed Web of Science ®Google Scholar
• Adrianzen Herrera DA, Fleisig SB, Gartrell BA. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: on-label but without evidence. Invest New Drugs. 2017;35:665–668.
   PubMed Web of Science ®Google Scholar
• Fernandes DS, Lopes JM. Pathology, therapy and prognosis of papillary renal carcinoma. Future Oncol. 2015;11:121–132.
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105.
   PubMed Web of Science ®Google Scholar
• Inamura K. Translocation renal cell carcinoma: an update on clinicopathological and molecular features. Cancers (Basel). 2017;9:111.
   Web of Science ®Google Scholar
• Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230–240.
   PubMed Web of Science ®Google Scholar
• Argani P, Yonescu R, Morsberger L, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol. 2012;36:1516–1526.
   PubMed Web of Science ®Google Scholar
• Inamura K, Fujiwara M, Togashi Y, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012;36:35–42.
   PubMed Web of Science ®Google Scholar
• Rao Q, Williamson SR, Zhang S, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013;37:804–815.
   PubMed Web of Science ®Google Scholar
• Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37:1150–1163.
   PubMed Web of Science ®Google Scholar